Use and impact of psychotropic medication in pregnancy

Summary This PhD student will work within the landmark 'Generation Victoria' (GenV) cohort, targeting all 150,000 babies born over two years (Oct 2021-Oct 2023) and their mothers at all 58 birthing hospitals in the state of Victoria, comprising consent, biosamples, and wide-ranging exposures and outcomes including administrative and clinical data. The student will contribute to creating a unique whole-state prescribing dataset within GenV by linkage/access to both primary care/outpatient medicines (Pharmaceutical Benefits Scheme (PBS)) and birthing hospitals prescribing data during pregnancy and the perinatal period. They will map ante/perinatal psychotropic medication use in the GenV cohort and then use causal techniques (including consideration of regional variations in medication use) to assess impacts on perinatal and infant/toddler outcomes such as language development, fine motor skills, and body composition.

Project Details

Up to 20% of women suffer from mood or anxiety disorders during pregnancy, whose impacts on adverse pregnancy and child outcomes could be mitigated by antenatal psychotropic medications (such as antidepressants, antipsychotics, sedative-hypnotics and other sleep medications). While these medications appear safe in pregnancy, the knowledge base is incomplete, so some mothers choose against needed medication due to fear it may affect their unborn baby.

This PhD student will work within the landmark 'Generation Victoria' (GenV) cohort, targeting all 150,000 babies born over two years (Oct 2021-Oct 2023) and their mothers at all 58 birthing hospitals in the state of Victoria, comprising consent, biosamples, and wide-ranging exposures and outcomes including administrative and clinical data. The student will contribute to creating a unique whole-state prescribing dataset within GenV by linkage/access to both primary care/outpatient medicines (Pharmaceutical Benefits Scheme (PBS)) and birthing hospitals prescribing data during pregnancy and the perinatal period. They will map ante/perinatal psychotropic medication use in the GenV cohort and then use causal techniques (including consideration of regional variations in medication use) to assess impacts on perinatal and infant/toddler outcomes such as language development, fine motor skills, and body composition.